PULMATRIX, INC. Unamortized Debt Issuance Expense
PULMATRIX, INC. (PULM) had Unamortized Debt Issuance Expense of $0 as of 2018-12-31, per its 10-K filed 2019-02-19.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:UnamortizedDebtIssuanceExpense · last filed 2019-02-19
- 2018-12-31: Unamortized Debt Issuance Expense $0.00.
- 2018-09-30: Unamortized Debt Issuance Expense $0.00.
- 2018-06-30: Unamortized Debt Issuance Expense $0.00.
- 2018-03-31: Unamortized Debt Issuance Expense $1.00K.
| Period end | Unamortized Debt Issuance Expense |
|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-02-19 |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-14 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-03 |
| 2018-03-31 | $1.00K 10-Q · filed 2018-05-11 |
| 2017-12-31 | $3.00K 10-K · filed 2019-02-19 |
| 2017-09-30 | $6.00K 10-Q · filed 2017-11-09 |
| 2017-06-30 | $8.00K 10-Q · filed 2017-08-04 |
| 2017-03-31 | $11.00K 10-Q · filed 2017-05-05 |
| 2016-12-31 | $15.00K 10-K · filed 2018-03-13 |
| 2016-09-30 | $18.00K 10-Q · filed 2016-11-04 |
| 2016-06-30 | $23.00K 10-Q · filed 2016-08-04 |
| 2016-03-31 | $27.00K 10-Q · filed 2016-05-05 |
| 2015-12-31 | $31.00K 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |